Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: GlobalData
$250.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

ChronTech Pharma AB Announces Results from Controlled Clinical Study of ChronVac-C


Tuesday, 2 Apr 2013 01:25am EDT 

ChronTech Pharma AB announced that it has made the first analysis of 12 weeks treatment with interferon and ribavirin in patients with (n=17) or without (n=12) two monthly previous vaccinations with 500 micrograms ChronVac-C administered with Inovio's Medpulser. No serious adverse events were noted and the number of moderate adverse events were lower in the vaccinated group than in the non-vaccinated group. At treatment week 12.71% of the vaccinated group had less than 15 international units of HCV RNA as compared to 58% in the non-vaccinated group. As regards to number of patients who were virus negative at treatment week 12 in the vaccinated group 65% were HCV RNA negative as compared to 58% in the non-vaccinated group. All in all the study shows that ChronVac-C is very safe but the differences in treatment outcome so far were too low to be statistically significant.